C. Sekerke

发表

Effects of tunicamycin on the cell-surface binding, internalization and degradation of low-density lipoproteins in human fibroblasts.

P. Kwiterovich, S. Chatterjee, C. Sekerke, 1981, European journal of biochemistry.

Pyrazole inhibitors of HMG-CoA reductase: an attempt to dramatically reduce synthetic complexity through minimal analog re-design.

B. Tait, M. Kowala, G. Lu, 2007, Bioorganic & medicinal chemistry letters.

CI-1011 lowers lipoprotein(a) and plasma cholesterol concentrations in chow-fed cynomolgus monkeys.

R. Stanfield, H. Lee, R. Ramharack, 1998, Atherosclerosis.

Discovery of pyrrole-based hepatoselective ligands as potent inhibitors of HMG-CoA reductase.

G. Lu, J. Pfefferkorn, Chulho Choi, 2007, Bioorganic & medicinal chemistry.

Attenuation of plasma low density lipoprotein cholesterol by select 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in mice devoid of low density lipoprotein receptors.

M. Pape, B. Auerbach, C. Bisgaier, 1997, Journal of lipid research.

Expression of apolipoprotein[a] and plasminogen mRNAs in cynomolgus monkey liver and extrahepatic tissues.

R. Ramharack, C. Sekerke, M. Spahr, 1996, Journal of lipid research.

Retinoids inhibit primary cynomolgus monkey hepatocyte lipoprotein(a) levels.

R. Ramharack, C. Sekerke, M. Spahr, 1997, Biochemical and biophysical research communications.

Design and synthesis of hepatoselective, pyrrole-based HMG-CoA reductase inhibitors.

G. Lu, J. Pfefferkorn, M. Harris, 2007, Bioorganic & medicinal chemistry letters.

Inhibitors of cholesterol biosynthesis. 4. trans-6-[2-(substituted-quinolinyl)ethenyl/ethyl]tetrahydro-4-hydroxy-2 H-pyran-2-ones, a novel series of HMG-CoA reductase inhibitors.

B. Roth, D. Sliskovic, R. Newton, 1991, Journal of medicinal chemistry.

Inhibitors of cholesterol biosynthesis. 3. Tetrahydro-4-hydroxy-6-[2-(1H-pyrrol-1-yl)ethyl]-2H-pyran-2-one inhibitors of HMG-CoA reductase. 2. Effects of introducing substituents at positions three and four of the pyrrole nucleus.

C J Blankley, C. J. Blankley, D. Ortwine, 1991, Journal of medicinal chemistry.

Design and synthesis of novel, conformationally restricted HMG-CoA reductase inhibitors.

Yuntao Song, Bruce Auerbach, Lisa Dillon, 2007, Bioorganic & medicinal chemistry letters.

Discovery of novel hepatoselective HMG-CoA reductase inhibitors for treating hypercholesterolemia: a bench-to-bedside case study on tissue selective drug distribution.

Bo Feng, David B Duignan, Bruce Auerbach, 2011, Bioorganic & medicinal chemistry letters.

Hepatoselectivity of statins: design and synthesis of 4-sulfamoyl pyrroles as HMG-CoA reductase inhibitors.

Yuntao Song, Bruce Auerbach, Lisa Dillon, 2008, Bioorganic & medicinal chemistry letters.

Increased urinary excretion of glycosphingolipids in familial hypercholesterolemia.

P. Kwiterovich, S. Chatterjee, C. Sekerke, 1982, Journal of lipid research.

Alterations in cell surface glycosphingolipids and other lipid classes of fibroblasts in familial hypercholesterolemia.

P. Kwiterovich, S. Chatterjee, C. Sekerke, 1976, Proceedings of the National Academy of Sciences of the United States of America.

Development, validation, and interlaboratory comparison of an HMG-CoA reductase inhibition assay for quantitation of atorvastatin in plasma matrices.

L. Whitfield, C. Sekerke, Y. Shum, 1998, Therapeutic drug monitoring.

Divergent pharmacologic activities of PD 132301-2 and CL 277,082, urea inhibitors of acyl-CoA:cholesterol acyltransferase.

R. Homan, A. Essenburg, J. Cornicelli, 1993, The Journal of pharmacology and experimental therapeutics.

Substituted pyrazoles as hepatoselective HMG-CoA reductase inhibitors: discovery of (3R,5R)-7-[2-(4-fluoro-phenyl)-4-isopropyl-5-(4-methyl-benzylcarbamoyl)-2H-pyrazol-3-yl]-3,5-dihydroxyheptanoic acid (PF-3052334) as a candidate for the treatment of hypercholesterolemia.

Bruce Auerbach, Lisa Dillon, Jeffrey A Pfefferkorn, 2008, Journal of medicinal chemistry.

Inhibitors of cholesterol biosynthesis. 6. trans-6-[2-(2-N-heteroaryl-3,5-disubstituted- pyrazol-4-yl)ethyl/ethenyl]tetrahydro-4-hydroxy-2H-pyran-2-ones.

C. J. Blankley, R. Stanfield, B. Roth, 1992, Journal of medicinal chemistry.

Effects of tunicamycin on the binding and degradation of low density lipoproteins and glycoprotein synthesis in cultured human fibroblasts.

P. Kwiterovich, S. Chatterjee, C. Sekerke, 1979, The Journal of biological chemistry.